 | | Vol. 11.45 – 19 November, 2020 |
| |
|
|
| Scientists characterized IER3IP1, which regulates the endoplasmic reticulum (ER) function and ECM protein secretion crucial for tissue integrity, the dysregulation of which results in microcephaly.
[Science] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| To comprehensively characterize the T-cell immune microenvironment of CDK12-deficient prostate cancers, subsets of immunosuppressive CD4+FOXP3– T-cells were increased compared to CDK12-proficient controls.
[Clinical Cancer Research] |
|
|
|
| The authors engineered patterned substrates that recapitulated the biophysical properties of the early embryo and mediated the self-organization of “gastrulation-like” nodes in cultured human embryonic stem cells.
[Developmental Cell] |
|
|
|
| Investigators showed that the upregulation of SOX2 was central to cancer-associated fibroblasts (CAFs) promoting tumor malignancy, which was repressed by protein kinase Cζ (PKCζ). PKCζ deficiency activated the reprogramming of colonic fibroblasts to generate a predominant SOX2-dependent CAF population expressing the WNT regulator Sfrp2 as its top biomarker.
[Developmental Cell] |
|
|
|
| Circadian clocks are endogenous oscillators that generate cell-autonomous rhythms that govern cellular processes and are synchronized by external cues in the local macro- and micro-environments. The authors showed that within demyelinating lesions, astrocyte circadian clocks produced the Wnt inhibitors SFRP1 and SFRP5.
[Cell Reports] |
|
|
|
| The organized bundles of collagen and other ECM proteins that make up the bulk of tendon tissue are generated by proteins secreted by fibroblast-like cells called tenocytes. Scientists examined the spatial, temporal, and cell type-specific activation profile of canonical NF-κB signaling during tendon healing.
[Science Signaling] |
|
|
|
| Researchers assessed the hepatocellular carcinoma tumor expression of the ECM protein proteoglycan 4 and its potential pharmacologic activity either alone, or in combination with sorafenib and regorafenib.
[Cell Death & Disease] |
|
|
|
| Scientists performed an in-depth qualitative and quantitative (immuno-)histological analysis focusing on key-players of the inflammatory and remodeling cascades. First-generation tissue-engineered matrix-based heart valves were prone to chronic inflammation, showing a high presence of macrophages and α-SMA+ cells, hinge-area thickening, and delayed endothelialization.
[Scientific Reports] |
|
|
|
| Researchers tested the hypothesis that human perinatal stem cell-derived ECM promotes human induced pluripotent stem cell-derived cardiomyocyte maturation to a greater extent than mouse cell-derived ECM.
[Scientific Reports] |
|
|
|
| Scientists present the photosynthetic oxygen (O2) supply to mammalian cells within a volumetric ECM-like construct, whereby a 3D-bioprinted fugitive pattern encapsulating unicellular green algae (Chlamydomonas reinhardtii), served as a natural photosynthetic O2 generator.
[Matter] |
|
|
|
|
| The first step of the metastatic cascade is invasion, in which tumor cells penetrate their surrounding basement membrane and migrate through the ECM into the surrounding tissue. The authors summarize data from published literature on the effect of chromosomal instability and genetic mutations on cancer cell migration and invasion.
[British Journal of Cancer] |
|
|
|
| Scientists describe the known pro-/anti-inflammatory and fibrogenic properties of ECM proteins and damage-associated molecular patterns, with particular reference to the immunomodulatory properties of the ECM in the context of chronic liver disease.
[Frontiers in Immunology] |
|
|
|
| The authors summarize the structure of skeletal muscle tissue. The role of various hydrogels, biomaterials, and scaffolds as building blocks of complex skeletal muscle structures is then explored.
[Advanced Materials Interfaces] |
|
|
|
|
| Surface Oncology announced that both of its lead clinical programs, SRF617 (targeting CD39) and SRF388 (targeting IL-27 in the microenvironment), have achieved predefined criteria for advancement into combination and expansion stages of the ongoing Phase I trials.
[Surface Oncology, Inc.] |
|
|
|
| Jounce Therapeutics, Inc. have received a Study May Proceed Letter from the US FDA to begin a Phase I trial, named INNATE, for JTX-8064, their anti-Leukocyte Immunoglobulin Like Receptor B2 (LILRB2/ILT4) antibody. The INNATE trial represents the first time two wholly owned Jounce immunotherapies are combined to target two different immune cells in the tumor microenvironment.
[Jounce Therapeutics, Inc.] |
|
|
|
|
| Sep 7 – 11, 2022
Woods Hole, Massachusetts, United States |
|
|
|
|
|
| | St. Jude Children’s Research Hospital – Memphis, Tennessee, United States |
|
|
|
| | Stanford University – Stanford, California, United States |
|
|
|
| | Edward Via College of Osteopathic Medicine – Blacksburg, Virginia, United States |
|
|
|
| | Zhejiang University-University of Edinburgh Institute – Haining, China |
|
|
|
| | H. Lee Moffitt Cancer Center & Research Institute – Tampa, Florida, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
